{"id":745082,"date":"2015-11-05T08:43:00","date_gmt":"2015-11-05T08:43:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-samsung-bioepis-will-present-new-biosimilars-data-at-the-2015-acr-arhp-annual-meeting\/"},"modified":"2025-11-07T01:24:49","modified_gmt":"2025-11-07T06:24:49","slug":"merck-announces-samsung-bioepis-will-present-new-biosimilars-data-at-the-2015-acr-arhp-annual-meeting","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-samsung-bioepis-will-present-new-biosimilars-data-at-the-2015-acr-arhp-annual-meeting\/","title":{"rendered":"Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR\/ARHP Annual Meeting"},"content":{"rendered":"<p class=\"bwalignc\">       One-Year Phase 3 Data for Investigational Biosimilar Candidates SB4,        Enbrel (Etanercept) and SB2, Remicade (Infliximab) to be Presented for        the First Time     <\/p>\n<p class=\"bwalignc\">       New Pivotal 24-Week Phase 3 Data for SB5, an Investigational        Biosimilar of Humira (Adalimumab), to be Reported in Late-Breaking        Presentation     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that Samsung Bioepis will present new Phase 3 clinical<br \/>\n      data for three investigational immunology biosimilar candidates at the<br \/>\n      American College of Rheumatology (ACR) and the Association for<br \/>\n      Rheumatology Health Professionals (ARHP) 2015 Annual Meeting in San<br \/>\n      Francisco, Nov. 7-11.\n    <\/p>\n<p>\n      Merck and Samsung Bioepis have a collaborative agreement to develop and<br \/>\n      commercialize biosimilar candidates in immunology, oncology and<br \/>\n      diabetes. These products have been designed to help meet the growing<br \/>\n      needs of patients and healthcare systems worldwide. In September, SB4<br \/>\n      was approved by the Ministry of Food and Drug Safety in Korea,<br \/>\n      representing the first biosimilar product approval for Samsung Bioepis.<br \/>\n      Under Merck\u2019s partnership with Samsung Bioepis, MSD will market SB4 in<br \/>\n      Korea under the brand name BRENZYS\u2122 (etanercept).\n    <\/p>\n<p>\n      \u201cPatients living with rheumatoid arthritis and other chronic<br \/>\n      inflammatory diseases are faced with many challenges,\u201d said Dora Bibila,<br \/>\n      general manager, Merck Biosimilars. \u201cThrough our partnership with<br \/>\n      Samsung Bioepis, Merck is committed to commercializing biosimilar<br \/>\n      alternatives to existing biologic therapies, and we are excited by the<br \/>\n      opportunity to expand patient access to effective and more affordable<br \/>\n      treatment options.\u201d\n    <\/p>\n<p>\n      The following Samsung Bioepis data presentations are part of the<br \/>\n      official ACR program. Abstracts are available online through the ACR<br \/>\n      website at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.acrannualmeeting.org&amp;esheet=51218075&amp;newsitemid=20151105005905&amp;lan=en-US&amp;anchor=www.acrannualmeeting.org&amp;index=1&amp;md5=33613cb22bd399bf3e33274598c24207\" rel=\"nofollow\">www.acrannualmeeting.org<\/a>.\n    <\/p>\n<p>\n      <b>SB4 Enbrel (etanercept) data at ACR<\/b>\n    <\/p>\n<p class=\"bwmarginl1\">\n      <b>Abstract # 2055 \u2013 Oral Presentation:<\/b> A Phase III, Randomized,<br \/>\n      Double-Blind Clinical Study Comparing SB4, an Etanercept Biosimilar,<br \/>\n      with Etanercept Reference Product (Enbrel) in Patients with Moderate to<br \/>\n      Severe Rheumatoid Arthritis Despite Methotrexate Therapy: 52-week<br \/>\n      Results; <b>Monday, Nov. 9, 2:30 \u2013 4:00 p.m. PST<\/b>; Session Title:<br \/>\n      Rheumatoid Arthritis \u2013 Small Molecules, Biologics and Gene Therapy III:<br \/>\n      Biosimilars; <b>Location: West \u2013 First Floor<\/b>\n    <\/p>\n<p>\n      <b>SB2 Remicade (infliximab) data at ACR<\/b>\n    <\/p>\n<p class=\"bwmarginl1\">\n      <b>Abstract # 2056 \u2013 Oral Presentation:<\/b> A Randomized, Double-Blind,<br \/>\n      Phase III Study Comparing SB2, an Infliximab Biosimilar, to the<br \/>\n      Infliximab Reference Product (Remicade) in Patients with Moderate to<br \/>\n      Severe Rheumatoid Arthritis Despite Methotrexate Therapy: 54-Week<br \/>\n      Results; <b>Monday, Nov. 9, 2:30 \u2013 4:00 p.m. PST<\/b>; Session Title:<br \/>\n      Rheumatoid Arthritis \u2013 Small Molecules, Biologics and Gene Therapy III:<br \/>\n      Biosimilars; <b>Location: West \u2013 First Floor<\/b>\n    <\/p>\n<p>\n      <b>SB5 Humira (adalimumab) data at ACR<\/b>\n    <\/p>\n<p class=\"bwmarginl1\">\n      <b>Abstract # 8L \u2013 Late-Breaking Poster Presentation:<\/b> A Phase III,<br \/>\n      Randomized, Double-Blind Clinical Study Comparing SB5, an Adalimumab<br \/>\n      Biosimilar, with Adalimumab Reference Product (Humira) in Patients with<br \/>\n      Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy:<br \/>\n      24-Week Results; <b>Tuesday, Nov. 10, 9:00 \u2013 11:00 a.m. PST<\/b>; Session<br \/>\n      Title: ACR Late-Breaking Abstract Poster Presentations; <b>Location:<br \/>\n      South \u2013 Halls B-C (Poster Hall)<\/b>\n    <\/p>\n<p>\n      <b>About the Merck and Samsung Bioepis collaboration<\/b>\n    <\/p>\n<p>\n      Merck and Samsung Bioepis announced in February 2013 a collaboration to<br \/>\n      develop and commercialize in certain partnered territories multiple<br \/>\n      biosimilar candidates. In February 2014, the two companies expanded the<br \/>\n      collaboration to include MK-1293, an insulin glargine biosimilar<br \/>\n      candidate currently in Phase 3 clinical development for the treatment of<br \/>\n      patients with type 1 and type 2 diabetes. Under terms of the agreement,<br \/>\n      Samsung Bioepis is responsible for preclinical and clinical development,<br \/>\n      process development and manufacturing, clinical trials and regulatory<br \/>\n      registration, except for MK-1293, which Merck will continue to develop<br \/>\n      and manufacture. Merck will be responsible in its partnered territories<br \/>\n      for commercialization of all approved products resulting from the<br \/>\n      collaboration.\n    <\/p>\n<p>\n      The portfolio includes biosimilar candidates in immunology, oncology and<br \/>\n      diabetes. There are five candidates in Phase 3 development [Merck<br \/>\n      partnered territories]:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        SB4 Enbrel (etanercept) [worldwide ex-U.S.\/EU\/Japan]\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        SB2 Remicade (infliximab) [worldwide ex-EU\/Russia\/Turkey]\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        SB5 Humira (adalimumab) [worldwide ex-EU\/Russia\/Turkey]\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        SB3 Herceptin (trastuzumab) [worldwide]\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        MK-1293 Lantus (insulin glargine) [worldwide]\n      <\/li>\n<\/ul>\n<p>\n      Regulatory filings for each of these five biosimilar candidates are<br \/>\n      expected to occur in the Merck partnered territories in the 2015-2016<br \/>\n      timeframe.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51218075&amp;newsitemid=20151105005905&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=b5971ed5cd4fc16ed496d45010867704\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51218075&amp;newsitemid=20151105005905&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=ba6f720bd3d108146f18eccf52ecb1de\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51218075&amp;newsitemid=20151105005905&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=fbf65a90f0e08068b14e63cd33bf40e7\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2Fuser%2FMerck&amp;esheet=51218075&amp;newsitemid=20151105005905&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=669d13337e63c2e1bcb337213c3018e3\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51218075&amp;newsitemid=20151105005905&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=96d0f678cbe92fbeacd2ccdc1a03237a\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20151105005905r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>Robert Consalvo,        908-236-1127<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>Justin        Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>One-Year Phase 3 Data for Investigational Biosimilar Candidates SB4, Enbrel (Etanercept) and SB2, Remicade (Infliximab) to be Presented for the First Time New Pivotal 24-Week Phase 3 Data for SB5, an Investigational Biosimilar of Humira (Adalimumab), to be Reported in Late-Breaking Presentation Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Samsung Bioepis will present new Phase 3 clinical data for three investigational immunology biosimilar candidates at the American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP) 2015 Annual Meeting in San Francisco, Nov. 7-11. Merck and Samsung Bioepis have a collaborative agreement to develop and commercialize biosimilar candidates in immunology, oncology and diabetes. These products have been designed to help meet the growing needs of patients and healthcare systems worldwide. In September, SB4 was approved by the Ministry of Food and Drug Safety in Korea,<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-745082","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR\/ARHP Annual Meeting - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-samsung-bioepis-will-present-new-biosimilars-data-at-the-2015-acr-arhp-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR\/ARHP Annual Meeting - Merck.com\" \/>\n<meta property=\"og:description\" content=\"One-Year Phase 3 Data for Investigational Biosimilar Candidates SB4, Enbrel (Etanercept) and SB2, Remicade (Infliximab) to be Presented for the First Time New Pivotal 24-Week Phase 3 Data for SB5, an Investigational Biosimilar of Humira (Adalimumab), to be Reported in Late-Breaking Presentation Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Samsung Bioepis will present new Phase 3 clinical data for three investigational immunology biosimilar candidates at the American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP) 2015 Annual Meeting in San Francisco, Nov. 7-11. Merck and Samsung Bioepis have a collaborative agreement to develop and commercialize biosimilar candidates in immunology, oncology and diabetes. These products have been designed to help meet the growing needs of patients and healthcare systems worldwide. In September, SB4 was approved by the Ministry of Food and Drug Safety in Korea,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-samsung-bioepis-will-present-new-biosimilars-data-at-the-2015-acr-arhp-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:24:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-samsung-bioepis-will-present-new-biosimilars-data-at-the-2015-acr-arhp-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-samsung-bioepis-will-present-new-biosimilars-data-at-the-2015-acr-arhp-annual-meeting\\\/\",\"name\":\"Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR\\\/ARHP Annual Meeting - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-11-05T08:43:00+00:00\",\"dateModified\":\"2025-11-07T06:24:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-samsung-bioepis-will-present-new-biosimilars-data-at-the-2015-acr-arhp-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-samsung-bioepis-will-present-new-biosimilars-data-at-the-2015-acr-arhp-annual-meeting\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-samsung-bioepis-will-present-new-biosimilars-data-at-the-2015-acr-arhp-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR\\\/ARHP Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR\/ARHP Annual Meeting - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-samsung-bioepis-will-present-new-biosimilars-data-at-the-2015-acr-arhp-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR\/ARHP Annual Meeting - Merck.com","og_description":"One-Year Phase 3 Data for Investigational Biosimilar Candidates SB4, Enbrel (Etanercept) and SB2, Remicade (Infliximab) to be Presented for the First Time New Pivotal 24-Week Phase 3 Data for SB5, an Investigational Biosimilar of Humira (Adalimumab), to be Reported in Late-Breaking Presentation Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Samsung Bioepis will present new Phase 3 clinical data for three investigational immunology biosimilar candidates at the American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP) 2015 Annual Meeting in San Francisco, Nov. 7-11. Merck and Samsung Bioepis have a collaborative agreement to develop and commercialize biosimilar candidates in immunology, oncology and diabetes. These products have been designed to help meet the growing needs of patients and healthcare systems worldwide. In September, SB4 was approved by the Ministry of Food and Drug Safety in Korea,","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-samsung-bioepis-will-present-new-biosimilars-data-at-the-2015-acr-arhp-annual-meeting\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:24:49+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-samsung-bioepis-will-present-new-biosimilars-data-at-the-2015-acr-arhp-annual-meeting\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-samsung-bioepis-will-present-new-biosimilars-data-at-the-2015-acr-arhp-annual-meeting\/","name":"Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR\/ARHP Annual Meeting - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-11-05T08:43:00+00:00","dateModified":"2025-11-07T06:24:49+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-samsung-bioepis-will-present-new-biosimilars-data-at-the-2015-acr-arhp-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-samsung-bioepis-will-present-new-biosimilars-data-at-the-2015-acr-arhp-annual-meeting\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-samsung-bioepis-will-present-new-biosimilars-data-at-the-2015-acr-arhp-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR\/ARHP Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"f596dbc1-263e-496c-a5c9-ab6d22f544e5","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-Samsung-Bioepis-Will-Present-New-Biosimilars-Data-at-the-2015-ACRARHP-Annual-Meeting-2015.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745082","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745082\/revisions"}],"predecessor-version":[{"id":3674578,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745082\/revisions\/3674578"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745082"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745082"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}